JNJ-1813 is under clinical development by Johnson & Johnson and currently in Phase II for Partial Seizure. According to GlobalData, Phase II drugs for Partial Seizure have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how JNJ-1813’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JNJ-1813 overview
JNJ-1813 (ADX-71149) is under development for the treatment of partial seizures, panic disorders and post-traumatic stress disorder (PTSD). It is an oral non-dopaminergic drug. The drug candidate is a positive allosteric modulator of metabotropic glutamate subtype 2 receptors (mGluR2). The glutamate hypothesis of schizophrenia posits that the function of the N-methyl-D-Aspartate (NMDA) receptor is compromised in this disease. It was also under development for the treatment of anxiety in patients with major depressive disorder, and schizophrenia.
Johnson & Johnson overview
Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products and medical devices. The company conducts business through its operating companies. It provides pharmaceuticals for immune disorders, cancer, neurological disorders, infectious, cardiovascular, and metabolic diseases; and medical devices for use in cardiovascular, orthopaedic, neurovascular care, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, healthcare professionals and hospitals. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US) and Latin America. J&J is headquartered in New Brunswick, New Jersey, the US.
For a complete picture of JNJ-1813’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
